<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 01 Sep 2020 English Publisher:Elsevier BVJournal:Vaccine, volume 38, pages 6,184-6,189 (issn: 0264-410X,

Authors: Kochhar, Sonali; Excler, Jean-Louis; Kim, Denny; Robertson, James S.; Fast, Patricia E.; Condit, Richard C.; Drew, Stephen; +9 Authors

doi: 10.1016/j.vaccine.2020.07.028

pmid: 32747214

pmc: PMC7834840

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

- Summary
- Subjects
- Metrics

Abstract

Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.

Related Organizations

Florida Southern College
United States
Washington State University
United States
Paul Ehrlich Institut
Germany
University of Mary
United States
The Task Force for Global Health
United States

View all View all

Keywords

Benefit-risk, COVID-19 Vaccines, International Cooperation, Pneumonia, Viral, Risk Assessment, Article, Betacoronavirus, Immunogenicity, Vaccine, CEPI, Humans, COVID-19 ; Brighton Collaboration ; CEPI ; Benefit-risk ; Virus ; Vaccine ; Safety ; Inactivated ; Template, Drug Approval, Pandemics, General Veterinary, General Immunology and Microbiology, SARS-CoV-2, Template, Public Health, Environmental and Occupational Health, COVID-19, Civil Defense, Inactivated, Viral Vaccines, Brighton Collaboration, Virus, Infectious Diseases, Vaccines, Inactivated, Government Regulation, Molecular Medicine, Patient Safety, Safety, Coronavirus Infections, Vaccine

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	8
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%